All Life Sciences & Technology News
Top stories summarized by our editors
8/17/2018

Sixty-eight percent of 50 packaged baby food products contained "worrisome" levels of one or more heavy metals such as inorganic arsenic, cadmium, lead and mercury, and 30% may be a "potential health risk" if consumed daily, while all products had at least one heavy metal, according to a Consumer Reports study. The report also showed higher levels of at least one heavy metal, especially inorganic arsenic, in products with sweet potatoes and rice, while organic food products had similar odds of containing heavy metals compared with nonorganic products.

8/17/2018

Wave Life Sciences' WVE-210201, being developed as a treatment for patients with Duchenne muscular dystrophy, received orphan drug and rare pediatric disease designations from the FDA.

Full Story:
Seeking Alpha
More Summaries:
Wave Life Sciences, Wave, Duchenne, FDA
8/17/2018

Eisai's Lenvima, or lenvatinib, was approved by the FDA to treat patients with unresectable hepatocellular carcinoma in a first-line setting. The decision was backed by results from the REFLECT study, which showed statistically significant improvements in progression-free survival in patients when compared with sorafenib and Lenvima's noninferiority to sorafenib for overall survival, achieving a median overall survival of 13.6 months versus 12.3 months with sorafenib.

Full Story:
eMPR
8/17/2018

The FDA announced three initiatives as part of an effort to advance the development and safety of medical devices related to the current user fee reauthorization. The initiatives comprise releasing draft guidance on issuing certificates for devices exported from the US, establishing a summary reporting program to streamline device malfunction reporting and proposing a list of device accessories suitable for reclassification to Class I category.

More Summaries:
FDA
8/17/2018

Researchers found that the FDA's The Real Cost anti-smoking campaign prevented 175,941 at-risk adolescents ages 12 to 17 from becoming smokers from 2014 to 2016, yielding an estimated $31 billion in smoking-related cost savings. The findings were published in the American Journal of Preventive Medicine.

Full Story:
MM&M
More Summaries:
FDA
8/17/2018

University of Bristol spinout Ziylo was acquired by Novo Nordisk in a deal that could exceed $800 million from an upfront payment and development, regulatory and sales milestones. Ziylo's early-stage synthetic glucose binding molecule platform will be used to develop glucose-responsive insulins.

Full Story:
Seeking Alpha
8/17/2018

Sen. Chuck Grassley, R-Iowa, announced that the Environmental Protection Agency will not pursue a plan of attaching renewable identification numbers to ethanol exports. Grassley said he hopes that plans the EPA has regarding the Renewable Fuel Standard will not further hurt Iowa farmers and agriculture communities.

8/17/2018

Humira, Lyrica and Xeljanz spent $25 million each in TV ad dollars in July. Companies spent $165 million on TV pharma ads during the month, an increase from $155 million in June.

Full Story:
FiercePharma
More Summaries:
Xeljanz
8/17/2018

More people recall television drug ads better than digital ones, but consumers are more likely to ask their doctors for a specific drug after seeing a digital ad, according to a study by DRG Digital/Manhattan Research. Print, radio and billboard ads were behind TV and digital in terms of recall.

Full Story:
FiercePharma
8/17/2018

Scientists at Antiva Biosciences are working on a first-in-class topical treatment for cervical neoplasia linked to human papillomavirus that could replace surgery, but male gynecologists and investors have questioned the need for the drug. The treatment would be as easy as treating a yeast infection, but CEO Gail Maderis says only venture capital firms that had a female partner seemed interested, with the exception of Sofinnova Ventures' David Kabakoff, who says male VCs still can't figure out how they will make money in the field of women's health.